Key result
Imatinib treatment resulted in complete clinical, radiological, and molecular remission at 3 years in a patient with myeloid/lymphoid neoplasm with eosinophilia and PDGFRA rearrangement.
Why the study?
Myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRA, PDGFRB, FGFR1 and PCM1-JAK2 represent an uncommon cause of eosinophilic lung infiltrates.
Case Report (n=1)
No
Highlights the importance of identifying PDGFRA rearrangement in patients with eosinophilic lung infiltrates due to its excellent response to imatinib.
Testing for PDGFRA rearrangement may be considered in eosinophilic lung infiltrates; leaves open need for prospective imatinib trials.
BACKGROUND: Eosinophilic lung diseases represent a heterogeneous group of disorders with prominent infiltrate of eosinophils in lung interstitium and alveolar spaces. Peripheral blood eosinophilia is often present. Infections, drugs, allergens, toxic agents have to be evaluated as possible causes of eosinophilic lung infiltrates. The category of myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRA, PDGFRB, FGFR1 and PCM1-JAK2 represents an uncommon cause of eosinophilic lung infiltrate. CASE PRESENTATION: We report the case of a 70-year old man complaining of dry cough and dyspnea. Ground glass-opacities were seen on imaging studies and peripheral blood eosinophilia was present. A thorough step-wise patient's evaluation led to identify the clonal nature of eosinophilia and the diagnosis of myeloid/lymphoid neoplasm with eosinophilia and rearrangement of PDGFRA was made. CONCLUSIONS: Correlation with clinical history, laboratory tests and imaging studies is essential to achieve the correct diagnosis when facing with eosinophilic lung infiltrates. A prolonged eosinophilia can cause life-threatening organ damage. Identification of PDGFRA rearrangement, as in the present case, is particularly critical given the sensitivity and excellent response to imatinib, which has completely changed the natural history of this neoplasm.
No takes yet. Share an insight, caveat, or question.
Zanelli et al. (2019) conducted a case report in Myeloid/lymphoid neoplasm with eosinophilia and rearrangement of PDGFRA (n=1). Imatinib was evaluated on Clinical, radiological, and molecular remission. Imatinib treatment resulted in complete clinical, radiological, and molecular remission at 3 years in a patient with myeloid/lymphoid neoplasm with eosinophilia and PDGFRA rearrangement.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: